| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2801926204019 | 192620401 | VINCRISTINE/PHARMACHEMIE INJ.SOL 1MG/ML BT x 1 VIAL x 1 ML | 4.62 | 4.85 | 6.69 |
| 05/2018 | 2801926204026 | 192620402 | VINCRISTINE/PHARMACHEMIE INJ.SOL 1MG/ML BT x 1 VIAL x 2 ML | 6.67 | 7.00 | 9.65 |
For treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, acute panmyelosis
The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca<sup>2+</sup>-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.
IVN-RAT LD<sub>50</sub> 1300 mg/kg; IPR-MUS LD<sub>50</sub> 5.2 mg/kg
19-155 hours